{"id":"W4407700137","doi":"10.1200/jco.2025.43.5_suppl.538","title":"Efficacy outcomes with belzutifan versus everolimus by baseline disease characteristics and burden subgroups in the phase 3 LITESPARK-005 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pharmacogenetics and Drug Metabolism","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Everolimus; Internal medicine; Baseline (sea); Oncology; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003981597,0.0008111634,0.001180953,0.000287407,0.0003030737,0.000838406,0.000569818,0.0007904379,0.002429187],"category_scores_gemma":[0.001345886,0.0003187037,0.002007744,0.0003262768,0.0003888354,0.0006393233,0.0004016474,0.001401362,0.0004381314],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007062081,"about_ca_system_score_gemma":0.001177073,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001001432,"about_ca_topic_score_gemma":0.003162831,"domain_scores_codex":[0.9989921,0.000563062,0.0000574972,0.0001303145,0.0001032015,0.0001537477],"domain_scores_gemma":[0.9989513,0.0001773787,0.000319678,0.0000615969,0.00004717532,0.000442947],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9004259,0.006479434,0.05783393,0.0003207907,0.00359646,0.0000970846,0.0001143876,0.001025042,0.005328851,0.0001164752,0.002878474,0.02178309],"study_design_scores_gemma":[0.3715538,0.2493762,0.3659456,0.00008682684,0.003794838,0.0003816441,0.0001555935,0.002584064,0.002028681,0.0003729523,0.003642884,0.0000768208],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994657,0.001908117,0.0001907057,0.0001997028,0.00003782673,0.0004129338,0.001497822,0.00002799032,0.001067931],"genre_scores_gemma":[0.9945879,0.0003401559,0.0003199223,0.0004751408,0.00005054207,0.0004623104,0.003235714,0.00001032463,0.0005179772],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003981597,"threshold_uncertainty_score":0.02105689,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2079413223425243,"score_gpt":0.574952022184666,"score_spread":0.3670106998421417,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}